In vitro testing shows enhanced thrombolytic efficacy in clot reduction using rtPA and tirofiban in acute ischemic stroke, suggesting improved treatment strategies.
Key Points
Sequential administration of rtPA and tirofiban reduces clot weight by 37.9%, indicating enhanced thrombolytic efficacy.
Seventy human clots underwent 172 thrombolytic experiments, demonstrating significant outcomes across treatment arms.
Assessment used a three-dimensional printed arterial flow loop to replicate cerebral circulation for accurate in vitro testing.
Findings highlight the potential for optimized dual thrombolytic strategies in treating patients with acute ischemic stroke.